ClinicalTrials.gg
CompletedNCT05048784Updated Sep 18, 2023Results posted

A Study to Compare the Pharmacokinetics of Two Different Tablets of Sotorasib in Healthy Participants

A Phase 1 interventional study of Sotorasib in Healthy Participants, sponsored by Amgen. Completed at 2 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-18.

Sponsored by Amgen · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
145
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The primary objective of this study is to compare the pharmacokinetics (PK) of sotorasib dose A administered orally as 3 tablets (test) to sotorasib dose A administered orally as 8 tablets (reference).

02

Conditions studied

  • Healthy Participants

Keywords

  • Sotorasib
  • AMG 510
  • Bioequivalence
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male participants or female participants, between 18 and 60 years of age (inclusive), at the time of Screening.
  • , between 18 and 30 kg/m\^2 (inclusive), at the time of Screening.
  • Females of nonchildbearing potential.

Exclusion criteria

Exclusion Criteria:

  • Inability to swallow oral medication or history of malabsorption syndrome.
  • History of , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) and in consultation with the Sponsor.
  • Poor peripheral venous access.
  • History or evidence, at Screening or Check in, of disorder, condition, or disease, including history of myolysis, not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    Treatment Sequence ABC

    Participants will be administered sotorasib dose A orally in the following order: * Treatment A - as 3 tablets (test 1) * Treatment B - as 8 tablets (reference) * Treatment C - as 3 tablets (test 2)

    Drug: Sotorasib

  • Experimental
    Treatment Sequence BAC

    Participants will be administered sotorasib dose A orally in the following order: * Treatment B - as 8 tablets (reference) * Treatment A - as 3 tablets (test 1) * Treatment C - as 3 tablets (test 2)

    Drug: Sotorasib

Interventions

  • Oral tablet

    Also known as: AMG 510

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Sotorasib for Treatments A and B

    Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib. Plasma pharmacokinetic (PK) parameters of sotorasib were summarized per treatment received, regardless of treatment sequence, as pre-specified.

    Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 1 (Period 1) and Day 4 (Period 2)

  2. Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib for Treatments A and B

    Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib. Plasma PK parameters of sotorasib were summarized per treatment received, regardless of treatment sequence, as pre-specified.

    Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 1 (Period 1) and Day 4 (Period 2)

  3. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Sotorasib for Treatments A and B

    Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib. Plasma PK parameters of sotorasib were summarized per treatment received, regardless of treatment sequence, as pre-specified.

    Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 1 (Period 1) and Day 4 (Period 2)

Secondary outcomes

  1. Number of Participants Who Experienced a Treatment-emergent AE (TEAE)

    An AE is any untoward medical occurrence in a participant irrespective of a causal relationship with the study treatment. Any abnormal clinical laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (e.g., 12-lead electrocardiogram or vital signs measurements), including those that worsen from baseline, that are considered clinically significant in the medical and scientific judgment of the Investigator (i.e., not related to progression of underlying disease) were considered AEs.

    Time frame: Day 1 to Day 9

  2. Food Effect: Cmax of Sotorasib

    Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib.

    Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3)

  3. Food Effect: AUClast of Sotorasib

    Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib.

    Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3)

  4. Food Effect: AUCinf of Sotorasib

    Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib.

    Time frame: Predose (Hour 0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3)

07

Results

Posted Sep 18, 2023

Participant flow

Overall, 145 participants were enrolled in the study in the United States between 16 August 2021 and 18 February 2022.

Period 1
Participant flow — Period 1
MilestoneTreatment Sequence ABTreatment Sequence BATreatment Sequence ABCTreatment Sequence BAC
Started666667
Administered treatment a66060
Administered treatment b06607
Completed636567
Not completed3100
Withdrew: Adverse event3100
Period 2
Participant flow — Period 2
MilestoneTreatment Sequence ABTreatment Sequence BATreatment Sequence ABCTreatment Sequence BAC
Started636567
Administered treatment a06507
Administered treatment b63060
Completed636467
Not completed0100
Withdrew: Lost to follow-up0100
Period 3
Participant flow — Period 3
MilestoneTreatment Sequence ABTreatment Sequence BATreatment Sequence ABCTreatment Sequence BAC
Started0067
Administered treatment c0067
Completed0067
Not completed0000

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Sotorasib for Treatments A and B

Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib. Plasma pharmacokinetic (PK) parameters of sotorasib were summarized per treatment received, regardless of treatment sequence, as pre-specified.

Time frame:
Predose (Hour 0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 1 (Period 1) and Day 4 (Period 2)
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of Sotorasib for Treatments A and B
ng/mLTreatment ATreatment B
Maximum Observed Plasma Concentration (Cmax) of Sotorasib for Treatments A and B6650 ± 41.36540 ± 37.3
Statistical analysis
  • Treatment A vs Treatment B · Ratio of geometric least squares means: 1.009 · 90% CI 0.980 to 1.040The geometric least squares mean ratios and confidence intervals (Cls) were obtained by taking the exponential of the corresponding differences and Cls on the natural-log (In) scale.
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib for Treatments A and B

Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib. Plasma PK parameters of sotorasib were summarized per treatment received, regardless of treatment sequence, as pre-specified.

Time frame:
Predose (Hour 0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 1 (Period 1) and Day 4 (Period 2)
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib for Treatments A and B
h*ng/mLTreatment ATreatment B
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of Sotorasib for Treatments A and B27800 ± 51.127500 ± 41.6
Statistical analysis
  • Treatment A vs Treatment B · Ratio of geometric least squares means: 1.010 · 90% CI 0.967 to 1.055The geometric least squares mean ratios and Cls were obtained by taking the exponential of the corresponding differences and Cls on the In scale.
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Sotorasib for Treatments A and B

Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib. Plasma PK parameters of sotorasib were summarized per treatment received, regardless of treatment sequence, as pre-specified.

Time frame:
Predose (Hour 0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 1 (Period 1) and Day 4 (Period 2)
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Sotorasib for Treatments A and B
h*ng/mLTreatment ATreatment B
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of Sotorasib for Treatments A and B28600 ± 48.127700 ± 41.5
Statistical analysis
  • Treatment A vs Treatment B · Ratio of geometric least squares means: 1.020 · 90% CI 0.977 to 1.065The geometric least squares mean ratios and Cls were obtained by taking the exponential of the corresponding differences and Cls on the In scale.
SecondaryNumber of Participants Who Experienced a Treatment-emergent AE (TEAE)

An AE is any untoward medical occurrence in a participant irrespective of a causal relationship with the study treatment. Any abnormal clinical laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety assessments (e.g., 12-lead electrocardiogram or vital signs measurements), including those that worsen from baseline, that are considered clinically significant in the medical and scientific judgment of the Investigator (i.e., not related to progression of underlying disease) were considered AEs.

Time frame:
Day 1 to Day 9
Reported as:
Count of participants · Participants
Number of Participants Who Experienced a Treatment-emergent AE (TEAE)
ParticipantsTreatment ATreatment BTreatment C
Number of Participants Who Experienced a Treatment-emergent AE (TEAE)8100
SecondaryFood Effect: Cmax of Sotorasib

Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib.

Time frame:
Predose (Hour 0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3)
Reported as:
Geometric mean · ng/mL
Food Effect: Cmax of Sotorasib
ng/mLTreatment ATreatment BTreatment C
Food Effect: Cmax of Sotorasib6390 ± 34.66790 ± 28.96400 ± 19.0
Statistical analysis
  • Treatment A vs Treatment C · Ratio of geometric least squares means: 1.001 · 90% CI 0.836 to 1.199The geometric least squares mean ratios and Cls were obtained by taking the exponential of the corresponding differences and Cls on the In scale.
SecondaryFood Effect: AUClast of Sotorasib

Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib.

Time frame:
Predose (Hour 0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3)
Reported as:
Geometric mean · h*ng/mL
Food Effect: AUClast of Sotorasib
h*ng/mLTreatment ATreatment BTreatment C
Food Effect: AUClast of Sotorasib23900 ± 40.826100 ± 31.134500 ± 19.2
Statistical analysis
  • Treatment A vs Treatment C · Ratio of geometric least squares means: 1.447 · 90% CI 1.200 to 1.745The geometric least squares mean ratios and Cls were obtained by taking the exponential of the corresponding differences and Cls on the In scale.
SecondaryFood Effect: AUCinf of Sotorasib

Blood samples were collected by venipuncture or cannulation for measurement of plasma concentrations of sotorasib.

Time frame:
Predose (Hour 0), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, 36, and 48 hours postdose following administration of sotorasib on Day 1 (Period 1), Day 4 (Period 2), and Day 7 (Period 3)
Reported as:
Geometric mean · h*ng/mL
Food Effect: AUCinf of Sotorasib
h*ng/mLTreatment ATreatment BTreatment C
Food Effect: AUCinf of Sotorasib23500 ± 41.026500 ± 30.334700 ± 19.2
Statistical analysis
  • Treatment A vs Treatment C · Ratio of geometric least squares means: 1.484 · 90% CI 1.236 to 1.783The geometric least squares mean ratios and Cls were obtained by taking the exponential of the corresponding differences and Cls on the In scale.

Adverse events

Collected over Day 1 to Day 9. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A0/145 (0%)0/145 (0%)8/145 (5.5%)
Treatment B0/145 (0%)0/145 (0%)10/145 (6.9%)
Treatment C0/13 (0%)0/13 (0%)0/13 (0%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventTreatment ATreatment BTreatment C
NauseaGastrointestinal disorders3/1450/1450/13
VomitingGastrointestinal disorders2/1451/1450/13
HeadacheNervous system disorders2/1451/1450/13
LymphadenitisBlood and lymphatic system disorders0/1451/1450/13
VertigoEar and labyrinth disorders1/1450/1450/13
Abdominal painGastrointestinal disorders1/1450/1450/13
DiarrhoeaGastrointestinal disorders1/1450/1450/13
Faeces discolouredGastrointestinal disorders0/1451/1450/13
Influenza like illnessGeneral disorders0/1451/1450/13
Covid-19Infections and infestations1/1450/1450/13

Baseline characteristics

The safety population included all participants who received at least 1 dose of sotorasib and had at least 1 postdose safety assessment.

Age, Categorical
Age, Categorical(Participants)Treatment Sequence ABTreatment Sequence BATreatment Sequence ABCTreatment Sequence BACTotal
<=18 years00000
Between 18 and 65 years666667145
>=65 years00000
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence ABTreatment Sequence BATreatment Sequence ABCTreatment Sequence BACTotal
Female761115
Male596056130
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Sequence ABTreatment Sequence BATreatment Sequence ABCTreatment Sequence BACTotal
Hispanic or Latino27314163
Not Hispanic or Latino39352682
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Sequence ABTreatment Sequence BATreatment Sequence ABCTreatment Sequence BACTotal
American Indian or Alaska Native01001
Asian10001
Native Hawaiian or Other Pacific Islander00000
Black or African American26300460
White39346382
More than one race01001
Unknown or Not Reported00000
08

Study locations

2 sites
  • Covance Clinical Research Unit
    Daytona Beach, Florida 32117, United States
  • Covance Clinical Research Unit
    Dallas, Texas 75247, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Feb 2022, 6 months.

Results were first posted in Sep 2023, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2021
First posted
Sep 17, 2021
StartActual
Aug 16, 2021
Primary completionActual
Feb 18, 2022
CompletionActual
Feb 18, 2022
Results first posted
Sep 18, 2023
Last update
Sep 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05048784
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 17, 2021
Start date
Aug 16, 2021
Primary completion
Feb 18, 2022
Completion
Feb 18, 2022
Results posted
Sep 18, 2023
Last update
Sep 18, 2023

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotorasib

Start the discussion